<DOC>
	<DOCNO>NCT03060720</DOCNO>
	<brief_summary>This research study look people cancer pancreas find clinical factor explain presence genetic mutation</brief_summary>
	<brief_title>Systematic Hereditary Pancreatic Cancer Risk Assessment Implications Personalized Therapy</brief_title>
	<detailed_description>This research do identify pancreatic cancer patient undergo genetic evaluation . A patient 's personal family history cancer information typically use make decision , currently accurate , evidence-based guideline exist help doctor use information make decision . The investigator hope test new pancreatic cancer patient , determine clinical factor predict genetic mutation order create risk assessment tool . The investigator want determine patient pancreatic cancer benefit genetic testing . To , investigator offer patient pancreatic cancer Dana-Farber Gastrointestinal Oncology clinic referral genetic evaluation . At Cancer Genetics Prevention clinic appointment , provider review patient 's personal familial history cancer offer genetic testing .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<criteria>Diagnosis pancreatic ductal adenocarcinoma Signed initial informed consent Participant agree genetic counsel Prospective participant unable sign inform consent base refer physician recommendation . Patient neuroendocrine pancreatic tumor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Pancreatic Cancer</keyword>
</DOC>